Han's Substack
Han Seoul Ohno, Sanya SSVDoing research on mainly life sciences stocks.
| Platform |  | Pricing | Freemium | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 33 | Founded | 2 years ago | Last Issue | 3 days ago |
| Active | |||||
Read this Newsletter
hanseoulohno.substack.comLatest Issues
Speculative Series: Tenax Therapeutics Inc (TENX)
At a 25% priced in PoS, if you see this as a 50:50 coinflip and see a clean success as $45-60 then this seems like an attractive speculative position.
The first in a speculative series, I aim to keep these short and to the point rather tha...
August Update: Portfolio & Some Thoughts on more Picks
#9 Updates on CCCC (a word on NKTR & BBIO), and upcoming speculative notes coming out for this month.
I’m starting a new series this month for paid subscribers to highlight more ‘speculative opportunities’ that I’m looking at - partly beca...
Nektar Therapeutics: (Rez)t and Forget
Nektar (NKTR) is a company that many funds (and bio veterans) will know - though I suspect not necessarily with rosy memories. I wrote on NKTR back in August 2025 (almost a year ago) when the SP was at $29. At highs this year it was up >240...
How to Read Atopic Dermatitis: EASI, IGA, Itch and Durability
Clinical Measurement Framework
AD is a mix of visible inflammatory skill signs, body-area involvement, itch, sleep disruption, QoL burden and chronic relapse risk. A good AD drug thus needs to improve both what the physician can see and wh...
July Update: Portfolio & Some Thoughts on more Picks
#8 ABVX Safety Scared Put to Rest, and XBI running hot
I promise that I am still writing on Nektar! I’ve been stuck in a writer’s block… Anyhow for this month.
Audience Metrics
Subscribers, engagement, traffic and sponsorship for Han's Substack.
| Subscribers | Engagement | 72 | Monthly Web Visits | ||
|---|---|---|---|---|---|
| Accepts Sponsors | Estimated Cost per Ad | ||||
Explore More
Authors
The writers behind this newsletter.
World’s worst computational biologist. Nothing I write is investment advice, please do your own due diligence.
likes are bookmarks, not endorsements. Do your own DD. Not investment advice--for entertainment purposes only. BTW not long TRAW since dec 2025
Frequently Asked Questions
How can I access the email archive for Han's Substack?
You can find recent issues that have been published by Han's Substack on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does Han's Substack have?
To see how many people subscribe to Han's Substack, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in Han's Substack?
Newsletter advertising can be extremely effective when it's done right. Before you pitch Han's Substack as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like Han's Substack?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact Han's Substack using the contact information provided and ask for a copy of their media kit.
How can I find newsletters related to Han's Substack?
Scroll up to where it says Related Newsletters to see other publications like Han's Substack. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact Han's Substack?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.